Table 1 Shows baseline characteristics of the patients in the included studies
Study ID | Study group | Age(year) Mean(SD) | BMI (kg/m2) Mean(SD) | Sex, NO. of females (%) | Physical status | ||
|---|---|---|---|---|---|---|---|
ASAI N(%) | ASAII N(%) | ASAIII N(%) | |||||
Bober2020 [27] | FICB | 62.9(13.03) | – | 31(53%) | – | – | – |
Chen 2023 [37] | FICB | 74(6.13) | 22.64(2.60) | 29(64.4%) | 0 (0%) | 31 (68.9%) | 14(31.1%) |
Placebo | 72(7.7) | 22.12(2.09) | 26(59.1%) | 0 (0%) | 31 (70.5%) | 13(29.5%) | |
Placebo | 63.9(13.03) | – | 36(60%) | – | – | – | |
Deniz2014 [23] | FICB | 59.1 ± 13.1 | 12(60%) | 12(60%) | 6(30%) | 2(10%) | |
Placebo | 62.2 ± 13.7 | 12(60%) | 5(25%) | 10(50%) | 5(25%) | ||
Desmet2017 [26] | FICB | 60.4(10.08) | 27.3(4) | 23(54.76%) | – | – | – |
Placebo | 66.5(12.4) | 27.3(4.5) | 29(67.44%) | – | – | – | |
Gola2021 [24] | FICB | 65(12) | 27(3) | 29(58%) | – | 23(46%) | 27(54%) |
Placebo | 65(9) | 28.1(2.9) | 28(56%) | – | 34(68%) | 16(32%) | |
Liu2020 [28] | FICB | 70.05(5.52) | 23.24(3.13) | 11(29.73%) | – | – | – |
Placebo | 70(5.69) | 23.05(2.89) | 12(32.43%) | – | – | – | |
Shariat2013 [29] | FICB | 61(9) | 30(7) | 9(56.25%) | – | – | – |
Placebo | 57(13) | 30(7) | 8(50%) | – | – | – | |
Stevens2007 [25] | FICB | 68.7(9.7) | – | 7(32%) | 3(14%) | 11(52%) | 7(33%) |
Placebo | 66.8(9.1) | – | 11(50%) | 5(23%) | 12(55%) | 5(23%) | |